Concepedia

Hilary Calvert

HC

49

Publications

5.7K

Citations

32

H-Index

1993

Active since

Affiliations

Newcastle University(Current)

Royal Marsden Hospital

University College London

North Tyneside General Hospital

Beatson West of Scotland Cancer Centre

Hilary Calvert is an author at Newcastle University specializing in medicine, oncology, and cancer therapeutics.

Top concepts

Publications per year

1993–2019

49

Publications

49

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

José Baselga, Danny Rischin, Malcolm Ranson et al. · Journal of Clinical Oncology · 2002 · 829 citations

Temozolomide and treatment of malignant glioma.

Henry S. Friedman, Tracy Kerby, Hilary Calvert · PubMed · 2000 · 725 citations

, , +15

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

Ruth Plummer, Christopher J. Jones, Mark R. Middleton et al. · Clinical Cancer Research · 2008 · 380 citations · Full text

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours

Ruth Plummer, Richard H. Wilson, Hilary Calvert et al. · British Journal of Cancer · 2011 · 378 citations · Full text

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Timothy A. Yap, Laura Vidal, Jan Adam et al. · Journal of Clinical Oncology · 2010 · 342 citations · Full text

Rows per page

1–5 of 49